Spyre Therapeutics, Inc. SYRE Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s other operating expenses?
- Spyre Therapeutics, Inc. (SYRE) reported other operating expenses of $45.64M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s other operating expenses changed year-over-year?
- Spyre Therapeutics, Inc.'s other operating expenses decreased by 14.8% year-over-year, from $53.57M to $45.64M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s other operating expenses?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s other operating expenses has grown at a 25.5% compound annual growth rate (CAGR), from $84.39M to $209.56M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.